News
Aurinia announces outcome of AUDREY clinical trial evaluating voclosporin ophthalmic solution in dry eye syndrome.
Aurinia Pharmaceuticals Inc. , a late-stage clinical biopharmaceutical company, announced topline data from the Phase II/III AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES).
The trial did not achieve statistical significance on its primary endpoint of a 10mm or greater improvement in STT at four weeks between active dose groups of VOS compared to vehicle. Aurinia is suspending the development program for VOS based upon these results.
Condition: Dry Eye Syndrome
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.